A seven-year old Cambridge biotech which last month launched its diagnostic test for prostate cancer is today announcing the results of a study showing the test can identify aggressive forms of the disease with 90 percent accuracy. Metamark is announcing the results of a study involving biopsies from 274 patients today at the annual meeting of the American Society of Clinical Oncology in Chicago. The samples were analyzed by the company’s ProMark diagnostic test, which is designed to help differentiate between patients who need invasive treatment from those who don’t need it.
Help employers find you! Check out all the jobs and post your resume.
